Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy geldnutzer

Regeneron Pharmaceuticals Inc.
Start price
€453.60
01.09.17 / 50%
Target price
€526.00
04.11.21
Performance (%)
-3.53%
End price
€437.60
19.11.20
Summary
This prediction ended on 19.11.20 with a price of €437.60. With a performance of -3.53%, the BUY prediction for Regeneron Pharmaceuticals Inc. by geldnutzer closed slightly in the red. geldnutzer has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y 3y
Regeneron Pharmaceuticals Inc. -1.120% -1.120% 15.386% 105.699%
iShares Core DAX® 1.051% -1.833% 12.822% 15.392%
iShares Nasdaq 100 -0.547% -3.738% 40.625% 42.396%
iShares Nikkei 225® -1.778% -8.115% 16.092% 0.891%
iShares S&P 500 0.002% -2.226% 28.387% 41.095%

According to geldnutzer what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?

Pros
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Small challenges to pay loans and raise capital
Very valuable balance sheet
Top Rating
Very positive Cash Flow expected
Capable Management
Leading role in innovation
Strong uniques
Very differentiated customer and product portfolio
Growths much faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Small Risks for its business
Market Leader or Top 3
Very Future proof/growth oriented business model
Could be worthwhile Investment >10% per year
Small cyclical dependencies
Known brand
Cons

Comments by geldnutzer for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) -3.53%
Target price 536.690
Change
Ends at 04.11.21

geldnutzer stimmt dem Sentiment von 'Sell' nicht zu

geldnutzer stimmt am 01.09.2017 dem Sell-Gesamtsentiment mit dem Kursziel 485.0$ nicht zu.

geldnutzer 
0
Report Share
01.09.17
Prediction Buy
Perf. (%) -3.53%
Target price 436.690
Change
Ends at 04.11.21

Kursziel geändert auf 436,69

geldnutzer 
1
Report Share
12.03.20
Prediction Buy
Perf. (%) -3.53%
Target price 456.690
Change
Ends at 04.11.21

Kursziel geändert auf 456,69

geldnutzer 
1
Report Share
30.03.20
Prediction Buy
Perf. (%) -3.53%
Target price 486.690
Change
Ends at 04.11.21

Kursziel geändert auf 486,69

geldnutzer 
2
Report Share
08.04.20
Prediction Buy
Perf. (%) -3.53%
Target price 496.690
Change
Ends at 04.11.21

Kursziel geändert auf 496,69

geldnutzer 
2
Report Share
14.04.20
Prediction Buy
Perf. (%) -3.53%
Target price 596.690
Change
Ends at 04.11.21

Kursziel geändert auf 596,69

geldnutzer 
1
Report Share
18.04.20
Prediction Buy
Perf. (%) -3.53%
Target price 536.690
Change
Ends at 04.11.21

Kursziel geändert auf 536,69

geldnutzer 
0
Report Share
26.05.20
Prediction Buy
Perf. (%) -3.53%
Target price 566.000
Change
Ends at 04.11.21

Kursziel geändert auf 566,0

geldnutzer 
0
Report Share
30.05.20
Prediction Buy
Perf. (%) -3.53%
Target price 586.000
Change
Ends at 04.11.21

Kursziel geändert auf 586,0

geldnutzer 
0
Report Share
23.06.20
Prediction Buy
Perf. (%) -3.53%
Target price 596.000
Change
Ends at 04.11.21

Kursziel geändert auf 596,0

geldnutzer 
0
Report Share
20.07.20
Prediction Buy
Perf. (%) -3.53%
Target price 566.000
Change
Ends at 04.11.21

Kursziel geändert auf 566,0

geldnutzer 
0
Report Share
28.07.20
Prediction Buy
Perf. (%) -3.53%
Target price 536.000
Change
Ends at 04.11.21

Kursziel geändert auf 536,0

geldnutzer 
0
Report Share
11.08.20
Prediction Buy
Perf. (%) -3.53%
Target price 546.000
Change
Ends at 04.11.21

Kursziel geändert auf 546,0

geldnutzer 
0
Report Share
19.08.20
Prediction Buy
Perf. (%) -3.53%
Target price 516.000
Change
Ends at 04.11.21

Kursziel geändert auf 516,0

geldnutzer 
0
Report Share
23.09.20
Prediction Buy
Perf. (%) -3.53%
Target price 536.000
Change
Ends at 04.11.21

Kursziel geändert auf 536,0

geldnutzer 
0
Report Share
13.10.20
Prediction Buy
Perf. (%) -3.53%
Target price 506.000
Change
Ends at 04.11.21

Kursziel geändert auf 506,0

geldnutzer 
0
Report Share
21.10.20
Prediction Buy
Perf. (%) -3.53%
Target price 526.000
Change
Ends at 04.11.21

Kursziel geändert auf 526,0

geldnutzer 
0
Report Share
04.11.20
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) -3.53%
Target price 526.000
Change
Ends at 04.11.21

Buy beendet

geldnutzer 
0
Report Share
19.11.20

Stopped prediction by geldnutzer for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€442.80
23.11.20
€555.00
23.11.21
29.97%
24.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
geldnutzer 
23.11.20 80%
sell
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€437.60
19.11.20
€426.00
19.11.21
1.19%
23.11.20

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
geldnutzer 
19.11.20 50%